Interleukin-1 (IL-1) Market by Type (Anakinra, Rilonacept, Canakinumab, and Gintuit), and Application (Arthritis and Inflammatory Diseases) – Market Size & Forecast, 2019-2030

Report ID : 215  |  Published Date : Jun 2020  |  Pages : 170  |  Region : Global  |  Report Code : PH-14





Interleukin-1 (IL-1) Market Overview and Introduction               

Interleukin-1 (IL-1) constitutes of a group of 11 cytokines, which play a vital role in regulating inflammatory & immune response against infections. The family of Interleukin-1 (IL-1) majorly constitutes of two distinct proteins, viz. IL-1 beta and IL-1 alpha. The functionality of IL-1 is not only limited to inflammation, but it also plays a role in regulating insulin secretion & fever, bone remodeling & formation, and neuronal phenotype development among others. IL-1 is an extremely active pro-inflammatory cytokine which significantly increases pain thresholds. The mono-therapeutic blockage of IL-1 activity in auto-inflammatory syndromes, considerably reduces pain and severity of the disease.  

IL-1 plays a crucial role in neuroinflammation. During an episode of inflammation, the quantity of IL-1 increases significantly, which in turn increases the chances of breakdown of the blood-brain barrier. Therapeutic application of blocking agents or drugs, blocks the biological activity of IL-1, which leads to swift improvement in clinical symptoms. The growth of the Interleukin-1 market can be attributed to the efficacy of the drug, as its application extensively improves inflammation and symptoms for conditions such as rheumatoid arthritis, immune-mediated inflammatory conditions, and other forms of autoinflammatory diseases. Moreover, rising cases of arthritis and strong product pipeline of IL-1 drugs by major pharmaceutical manufacturers are few of the other factors contributing to the significant growth of the global Interleukin-1 market. However, probability of serious allergic reactions such as anaphylactic reactions, may hinder the global Interleukin-1 market to a certain extent.

The global Interleukin-1 (IL-1) market is majorly classified into three segments, viz. by type, application, end user and region.

Interleukin-1 (IL-1) Market by Type

The segment of type can be classified into the following categories, anakinra, rilonacept, canakinumab, gintuit and other types

Interleukin-1 (IL-1) Market by Application

On the basis of application, the Interleukin-1 (IL-1) market is bifurcated into, arthritis, inflammatory diseases and other applications (type 2 diabetes, epilepsy, & cancer).

Interleukin-1 (IL-1) Market by Region

The global Interleukin-1 (IL-1) market can be segmented into North America, Asia Pacific, Europe and Rest of World (ROW). The global Interleukin-1 (IL-1) market is driven by rising cases of orthopedic ailments, such as osteoarthritis, rheumatoid arthritis and other disorders such as periodic fever syndromes such as Cryopyrin-Associated Periodic Syndrome (CAPS), Neonatal-Onset Multisystem Inflammatory Disease (NOMID) and Tumor Necrosis Factor Receptor-Associated Periodic Syndrome (TRAPS) among others.

Interleukin-1 (IL-1) Market Prominent Players

The prominent players operating in the global Interleukin-1 (IL-1) market are Swedish Orphan Biovitrum AB, Regeneron Pharmaceuticals, Inc., Novartis AG, Vertex Pharmaceuticals Incorporated, XBiotech, Creative Biolabs and other prominent players.